The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bdsi.com

Founded Year

1997

Stage

Acq - P2P | Acquired

Valuation

$0000 

Revenue

$0000 

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that leverages its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.On March 23rd, 2022, BioDelivery Sciences International was acquired by Collegium Pharmaceutical.

BioDelivery Sciences International Headquarter Location

4131 ParkLake Avenue Suite 225

Raleigh, North Carolina, 27612,

United States

919-582-9050

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

BioDelivery Sciences International Patents

BioDelivery Sciences International has filed 51 patents.

The 3 most popular patent topics include:

  • Morphinans
  • Phenols
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2012

2/27/2018

Analgesics, Morphinans, Phenols, Acute pain, Opioid antagonists

Grant

Application Date

12/21/2012

Grant Date

2/27/2018

Title

Related Topics

Analgesics, Morphinans, Phenols, Acute pain, Opioid antagonists

Status

Grant

Latest BioDelivery Sciences International News

Oral Solution of Celecoxib May Provide Migraine Relief as Early as 1 Hour

Jun 11, 2022

Post-hoc analysis of pooled data from pivotal trials (NCT03009019, NCT03006276) of a novel self-emulsifying oral celecoxib solution (Elyxyb; Biodelivery Sciences International, Stoughton, MA) show that it is safe and effective for acute treatment of migraine. This formulation of celecoxib reaches maximal dose (Tmax) at 42 minutes for potentially faster acute treatment of migraine. Pain freedom at 2 hours occurred in 34.4% of those who treated a migraine attack at onset with this formulation of celecoxib vs 24% with placebo (P=.0002; modified intent-to-treat analysis)....

BioDelivery Sciences International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioDelivery Sciences International Rank

  • When was BioDelivery Sciences International founded?

    BioDelivery Sciences International was founded in 1997.

  • Where is BioDelivery Sciences International's headquarters?

    BioDelivery Sciences International's headquarters is located at 4131 ParkLake Avenue, Raleigh.

  • What is BioDelivery Sciences International's latest funding round?

    BioDelivery Sciences International's latest funding round is Acq - P2P.

  • Who are the investors of BioDelivery Sciences International?

    Investors of BioDelivery Sciences International include Collegium Pharmaceutical, Broadfin Capital and The Hopkins Capital Group.

  • Who are BioDelivery Sciences International's competitors?

    Competitors of BioDelivery Sciences International include Armgo Pharma, Flexion Therapeutics, EyePoint Pharmaceuticals, Foamix Pharmaceuticals, Genocea Biosciences and 11 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

R
Regene Med

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

Presage Biosciences Logo
Presage Biosciences

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.

N
Neon

The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.

O
Optimata

Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.